Icosavax Initiates Phase 1/1b Trial of VLP Vaccine Candidate Against Respiratory Syncytial Virus
Icosavax, Inc. (ICVX)
Company Research
Source: GlobeNewswire
SEATTLE, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Icosavax, Inc. (NASDAQ: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, today announced the initiation of a Phase 1/1b clinical trial of IVX-121, a VLP displaying a Respiratory Syncytial Virus (RSV) stabilized pre-fusion F antigen, in healthy adults and older adults. Assuming favorable results from the IVX-121 Phase 1/1b clinical trial and favorable preclinical data from its human Metapneumovirus (hMPV) VLP candidate, Icosavax plans to thereafter initiate a Phase 1 clinical trial of its IVX-A12 bivalent RSV/hMPV vaccine candidate. “I am delighted with the clinical progress Icosavax has recently made. The initiation of our second clinical trial in just three months bears testament to the concerted effort our team exerted in the development and manufacturing of our vaccine candidates,” said Adam Simpson, Chief Executive Officer of Ic
Show less
Read more
Impact Snapshot
Event Time:
ICVX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ICVX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ICVX alerts
High impacting Icosavax, Inc. news events
Weekly update
A roundup of the hottest topics
ICVX
News
- M&A Funds And The Stocks Where There Is At Least A 3.5% Stake [Seeking Alpha]Seeking Alpha
- SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates ICVX, PGTI, IONMPR Newswire
- Icosavax: Tender Offer With Contingent Value Right [Seeking Alpha]Seeking Alpha
- INVESTIGATION ALERT: Halper Sadeh LLC Investigates CSTR, ICVX, BATLGlobeNewswire
- ICOSAVAX INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Icosavax, Inc. - ICVXPR Newswire
ICVX
Earnings
- 11/14/23 - Beat
ICVX
Sec Filings
- 2/21/24 - Form SC
- 2/21/24 - Form EFFECT
- 2/20/24 - Form 4
- ICVX's page on the SEC website